Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2020-12-02 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix and DuChemBio - South Korea Partnership 2 pages 222.1KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a commercialisation and partnership agreement between Telix Pharmaceuticals and DuChemBio for a prostate cancer imaging product. It contains no financial statements, regulatory filings, or detailed financial data. It is not an annual or interim report, audit report, earnings release, or any other formal financial filing. The content focuses on a business partnership and product commercialisation, which aligns with a Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes. The document length is 5669 characters, sufficient for a detailed announcement but not a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-12-02 English
ProstACT Phase III Study Clinical Development Update 2 pages 213.0KB
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Telix Pharmaceuticals Limited providing an update on the clinical development plan for their Phase III ProstACT study. It discusses regulatory interactions with the FDA, study design, patient enrollment plans, and clinical trial notifications. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on clinical development progress and regulatory feedback rather than financial results or management changes. The document is about a clinical development update and does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or legal proceeding update. Given the nature of the content, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-12-02 English
Overview of ProstACT Phase III Study - Investor supplement 8 pages 9.3MB
Investor Presentation Classification · 95% confidence The document is titled as an 'Investor Briefing Supplement' and provides detailed information about a Phase III clinical trial study of a drug candidate (177Lu-DOTA-rosopatamab) by Telix Pharmaceuticals. It includes study design, patient population, endpoints, and background clinical data. The content is structured as a presentation with slides, charts, and disclaimers, focusing on clinical trial data and study overview rather than financial results or regulatory filings. There is no indication that this is a full annual or interim report, audit report, earnings release, or regulatory filing. The document is clearly a detailed presentation aimed at investors, providing strategic and clinical development information. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length (8032 characters) and content support this classification with high confidence.
2020-12-02 English
FDA Approves 68Ga-PSMA Imaging for Use at UCLA and UCSF 1
Regulatory Filings Classification · 95% confidence The document is a press release announcing FDA approval of a specific imaging technology for use at certain institutions. It is a corporate announcement about regulatory approval of a product, not a financial report, earnings release, or detailed investor presentation. The document length is 3773 characters, which is relatively short and does not contain financial statements or detailed financial data. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing in the sense of compliance documents or certifications. The content is an announcement of a regulatory milestone related to product approval, which is best categorized under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-01 English
Approval for Ph I study of next generation product TLX592 2 pages 209.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals Limited has received approval to commence a first-in-human Phase I clinical trial for a new prostate cancer therapy product. It discusses the clinical trial approval, the technology behind the product, and background information about prostate cancer and the company. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a clinical trial approval and not a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not related to shareholder meetings, voting results, or capital changes. The content is primarily a corporate announcement about clinical trial approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-01 English
Investor Briefing on First-in-Human Translation of TLX592 13 pages 2.2MB
Investor Presentation Classification · 95% confidence The document is titled 'Telix Pharmaceuticals Limited: Investor Briefing' and dated 2nd December 2020. It contains detailed information about a new drug candidate TLX592, including its pharmacokinetics, clinical study design, dosing schedule, and commercial strategy. The content is presented as a detailed presentation with slides, images, and scientific data. There is no indication that this is a regulatory filing, earnings release, or an official report like an annual or interim report. The document is clearly a presentation aimed at investors, focusing on the drug's development, clinical trial plans, and strategic positioning. Therefore, the document fits the definition of an Investor Presentation (IP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2020-12-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.